Patrick Shahgaldian

Perseo pharma AG is a Swiss preclinical stage biopharmaceutical company that focuses on discovering and developing enzyme therapeutics for the treatment of digestive diseases. The company is based in Muttenz, Switzerland. The company has entered into a strategic research and development collaboration with Nestlé Health Science to develop novel therapies for digestive diseases. Perseo pharma's innovative technology is based on therapeutic enzymes that are protected in a nano shield with muco-adhesive coating. The company is a spin-off from the University of Applied Sciences (FHNW), School of Life Sciences in Switzerland, and was founded by Prof. Dr. Patrick Shahgaldian. Yves Dudal has been the CEO of the company since 2019.

Perseo pharma AG is a Swiss preclinical stage biopharmaceutical company that focuses on discovering and developing enzyme therapeutics for the treatment of digestive diseases. The company is based in Muttenz, Switzerland. The company has entered into a strategic research and development collaboration with Nestlé Health Science to develop novel therapies for digestive diseases. Perseo pharma's innovative technology is based on therapeutic enzymes that are protected in a nano shield with muco-adhesive coating. The company is a spin-off from the University of Applied Sciences (FHNW), School of Life Sciences in Switzerland, and was founded by Prof. Dr. Patrick Shahgaldian. Yves Dudal has been the CEO of the company since 2019.

Perseo pharma AG is a Swiss preclinical stage biopharmaceutical company that focuses on discovering and developing enzyme therapeutics for the treatment of digestive diseases. The company is based in Muttenz, Switzerland. The company has entered into a strategic research and development collaboration with Nestlé Health Science to develop novel therapies for digestive diseases. Perseo pharma's innovative technology is based on therapeutic enzymes that are protected in a nano shield with muco-adhesive coating. The company is a spin-off from the University of Applied Sciences (FHNW), School of Life Sciences in Switzerland, and was founded by Prof. Dr. Patrick Shahgaldian. Yves Dudal has been the CEO of the company since 2019.

Perseo pharma AG is a Swiss preclinical stage biopharmaceutical company that focuses on discovering and developing enzyme therapeutics for the treatment of digestive diseases. The company is based in Muttenz, Switzerland. The company has entered into a strategic research and development collaboration with Nestlé Health Science to develop novel therapies for digestive diseases. Perseo pharma's innovative technology is based on therapeutic enzymes that are protected in a nano shield with muco-adhesive coating. The company is a spin-off from the University of Applied Sciences (FHNW), School of Life Sciences in Switzerland, and was founded by Prof. Dr. Patrick Shahgaldian. Yves Dudal has been the CEO of the company since 2019.